AEMD News & Events

Aethlon Medical announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure". The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab", is being conducted to assess the Hemopurifier's safety, feasibility, and optimal dosing.

Aethlon Medical announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group to act as the company's exclusive financial advisor in connection with this process. The company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities. Maxim will assist the company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the company.

As of December 31, 2025, Aethlon had a cash balance of approximately $7M. "We remain committed to advancing our clinical programs and research initiatives with operational discipline," said James Frakes, CEO and CFO of Aethlon Medical. "Recent progress in our trials, research collaborations, and technology development continues to move us closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases."

Aethlon Medical files to sell 2.03M shares of common stock for holders